Pirfenidone
(USAN, rINN)
Synonyms: AMR-69; Pirfenidona; Pirfénidone; Pirfenidonum. 5-Methyl-1phenyl-2(1H)-pyridone.
Cyrillic synonym: Пирфенидон.
Chemical information
Chemical formula: C12H11NO = 185.2.
CAS — 53179-13-8.
Profile
Pirfenidone is an antifibrotic drug under investigation in disorders such as idiopathic pulmonary fibrosis, multiple sclerosis, and familial adenomatous polyposis.
◊ References.
1. Nicod LP. Pirfenidone in idiopathic pulmonary fibrosis. Lancet 1999; 354: 268–9
2. Walker JE, Margolin SB. Pirfenidone for chronic progressive multiple sclerosis. Multiple Sclerosis 2001; 7: 305–12
3. Nagai S, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41: 1118–23
4. Bowen JD, et al. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Multiple Sclerosis 2003; 9: 280–3
5. Lindor NM, et al. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 2003;98: 1868–74
6. Azuma A, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040–7
7. Walker JE, et al. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Multiple Sclerosis 2005; 11: 149–58
8. Babovic-Vuksanovic D, et al. Phase II trial of pirfenidone in adults with neurofibromatosis typ
1. Neurology 2006; 67: 1860–2
9. Shi S, et al. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007; 47: 1268–76.
2. Walker JE, Margolin SB. Pirfenidone for chronic progressive multiple sclerosis. Multiple Sclerosis 2001; 7: 305–12
3. Nagai S, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41: 1118–23
4. Bowen JD, et al. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Multiple Sclerosis 2003; 9: 280–3
5. Lindor NM, et al. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 2003;98: 1868–74
6. Azuma A, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040–7
7. Walker JE, et al. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Multiple Sclerosis 2005; 11: 149–58
8. Babovic-Vuksanovic D, et al. Phase II trial of pirfenidone in adults with neurofibromatosis typ
1. Neurology 2006; 67: 1860–2
9. Shi S, et al. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007; 47: 1268–76.
Published May 08, 2019.